SCHEMBL1333810

SCHEMBL1333810

O=C1NCc2c(Br)cccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK4 Q9HAZ1 3/20 1.00
CDK5 Q00535 2/20 1.00
DYRK1A Q13627 2/20 1.00
PIM1 P11309 2/20 1.00
ROCK1 Q13464 2/20 1.00
CSNK1A1 P48729 1/20 1.00
LRRK2 Q5S007 1/20 1.00
DYRK1B Q9Y463 1/20 1.00
PARP10 Q53GL7 3/20 0.68
PARP11 Q9NR21 3/20 0.68
LTK P29376 1/20 0.53
MST1R Q04912 1/20 0.53
CA12 O43570 1/20 0.48
CA9 Q16790 1/20 0.48
PIK3CD O00329 1/20 0.46
PIK3CA P42336 1/20 0.46
PIK3CB P42338 1/20 0.46
PARP1 P09874 5/20 0.46
KDR P35968 4/20 0.44
PLK4 O00444 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29644368 0.81 PARP10 (1.00) CLK4CDK5DYRK1APIM1ROCK1
SCHEMBL2999788 0.81 PARP10 (1.00) CLK4CDK5DYRK1APIM1ROCK1
SCHEMBL19643333 0.78 PARP10 (0.81) CLK4CDK5DYRK1APIM1ROCK1
SCHEMBL6297545 0.78 PARP1 (0.70) CLK4CDK5DYRK1APIM1ROCK1
SCHEMBL29532218 0.78 PARP1 (0.70) CLK4CDK5DYRK1APIM1ROCK1
SCHEMBL24148319 0.76 CDK5 (0.61) CLK4CDK5DYRK1APIM1ROCK1
SCHEMBL2379452 0.76 CDK5 (0.61) CLK4CDK5DYRK1APIM1ROCK1
SCHEMBL1078443 0.76 CDK5 (0.61) CLK4CDK5DYRK1APIM1ROCK1
SCHEMBL9475196 0.76 PARP1 (0.68) CLK4CDK5DYRK1APIM1ROCK1
SCHEMBL24142865 0.76 CDK5 (0.61) CLK4CDK5DYRK1APIM1ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260144881-A1 HPK1 TARGETING COMPOUNDS AND USES THEREOF ARVINAS OPERATIONS, INC. (US) 2026-05-28 US disclosed
EP-4747260-A1 MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2026-05-27 EP disclosed
EP-4731608-A1 ISOINDOLINONE-CONTAINING PARP INHIBITORS AND METHODS OF USE Valo Health, Inc. (US) 2026-04-29 EP disclosed
US-12590078-B2 2026-03-31 US disclosed
US-20250282785-A1 PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE JANSSEN PHARMACEUTICA NV (BE) 2025-09-11 US disclosed
EP-4567031-A1 HPK1 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF Beijing Earthwise Technology Co., Ltd. (CN) 2025-06-11 EP disclosed
CN-119790047-A HPK1 inhibitor, preparation method and application thereof 北京望实智慧科技有限公司 2025-04-08 CN disclosed
EP-4522608-A1 PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE JANSSEN Pharmaceutica NV (BE) 2025-03-19 EP disclosed
CN-119638639-A Biaryl compound with anti-cell necrotic apoptosis activity, derivative and application thereof 中国药科大学 2025-03-18 CN disclosed
CN-119546602-A Pyrrolidone derivatives as inhibitors of nfkb-induced kinase 詹森药业有限公司 2025-02-28 CN disclosed
EP-1528919-A2 THERAPEUTIC USE OF ARYL AMINO ACID DERIVATIVES Pfizer Limited (GB) 2005-05-11 EP disclosed
US-20050026976-A1 Isoindolinone kinase inhibitors ABBOTT LABORATORIES 2005-02-03 US disclosed
WO-2004108672-A1 ISOINDOLIN-1-ONE COMPOUNDS AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2004-12-16 WO disclosed
US-20040138197-A1 Therapeutic use of aryl amino acid derivatives MAW GRAHAM NIGEL (GB) 2004-07-15 US disclosed
US-20040072876-A1 Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-15 US disclosed
US-20040058970-A1 Cognition enhancing derivatives of isoxazole triazoloindane GABA-A alpha 5 receptor subunit ligands MERCK SHARP & DOHME LTD. (GB) 2004-03-25 US disclosed
WO-2004014357-A2 THERAPEUTIC USE OF ARYL AMINO ACID DERIVATIVES PFIZER LIMITED (GB) 2004-02-19 WO disclosed
EP-1348706-A1 SUBSTITUTED THIAZOLE DERIVATIVES BEARING 3-PYRIDYL GROUPS, PROCESS FOR PREPARING THE SAME AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2003-10-01 EP disclosed
US-6518257-B1 1-substituted phenyl-1-(1h-imidazol-4-yl) alcohols, process for producing the same and use thereof TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-02-11 US disclosed
EP-1227086-A1 1-SUBSTITUTED PHENYL-1-(1H-IMIDAZOL-4-YL) ALCOHOLS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2002-07-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260144881-A1 HPK1 TARGETING COMPOUNDS AND USES THEREOF SGK1, PBK, SGK3 CLK4 228/4885CDK5 1310/4885DYRK1A 663/4885
US-20040072876-A1 Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof CYP17A1, CYP21A2, HSD17B1 CLK4 4022/4885CDK5 1452/4885DYRK1A 4130/4885
US-12590078-B2 ADRM1, USP19, USP1 CLK4 4068/4885CDK5 623/4885DYRK1A 3133/4885
US-20040058970-A1 Cognition enhancing derivatives of isoxazole triazoloindane GABA-A alpha 5 receptor subunit ligands GABRA5, GABRA1, GABRB1 CLK4 3313/4885CDK5 1075/4885DYRK1A 3094/4885
US-20250282785-A1 PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE NFKBIA, IKBKG, IKBKB CLK4 1923/4885CDK5 487/4885DYRK1A 2524/4885
US-20040138197-A1 Therapeutic use of aryl amino acid derivatives CNR1, HCRTR1, HTR6 CLK4 3964/4885CDK5 1789/4885DYRK1A 2497/4885
US-20050026976-A1 Isoindolinone kinase inhibitors ABL1, LCK, MAP3K7 CLK4 604/4885CDK5 55/4885DYRK1A 532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.